drugset / Trial / NCT05514483
5-HT3 Receptor Antagonist and Respiratory Drive in Patients With ARDS
Phase 4
Unknown
10 enrolled
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Fonds de la Recherche en Santé du Québec · collab
Non-randomizedCrossoverOpen-labelTreatment
Summary
This is a pilot study aimed at acquiring primary physiological data, describing and estimating the effects of a 5-HT3 receptor antagonist (ondansetron) on respiratory drive in patients with acute respiratory distress syndrome (ARDS). The results of this study will determine the interest and feasibility of assessing the clinical applications of ondansetron in reducing patient self-inflicted lung injury (P-SILI) in ARDS, in subsequent studies.
Timeline
- Start
- 2022-11-10
- Primary completion
- 2024-03-06
- Completion
- 2024-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ondansetron | Other / unclassified | 0.15 mg/kg | Intravenous |